Biote Reports Fourth Quarter and Full Year 2023 Financial Results

Go back to Biote Reports Fourth Quarter and Full Year 2023 Financial Results

biote Corp. (BTMD) PT Raised to $9 at Roth/MKM

March 13, 2024 6:48 AM EDT

Roth/MKM analyst George Kelly raised the price target on biote Corp. (NASDAQ: BTMD) to $9.00 (from $8.00) while maintaining a Buy rating.

The analyst comments "BTMD's 4Q report was largely as expected following its January pre-release. We remain positive given BTMD's compelling valuation and still... More

biote Corp. (BTMD) PT Raised to $8.24 at Jefferies

March 13, 2024 5:46 AM EDT

Jefferies analyst Kaumil Gajrawala raised the price target on biote Corp. (NASDAQ: BTMD) to $8.24 (from $7.72) while maintaining a Buy rating.

The analyst comments "Q4 results largely in-line and 2024 guidance reaffirmed. New wellness offerings, the launch of the Men's health initiative, and... More

biote Corp. (BTMD) Tops Q4 EPS by 11c, Revenue In Line; Offers FY24 Revenue Guidance

March 12, 2024 4:13 PM EDT

biote Corp. (NASDAQ: BTMD) reported Q4 EPS of $0.18, $0.11 better than the analyst estimate of $0.07. Revenue for the quarter came in at $45.7 million versus the consensus estimate of $45.73 million.

GUIDANCE:

biote Corp. sees FY2024 revenue of $200-204 million, versus the consensus... More